Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 20/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23326548 | 1.00 | SOS1 (0.85) | SOS1 | |
| SCHEMBL29861735 | 1.00 | SOS1 (0.85) | SOS1 | |
| SCHEMBL23344809 | 0.92 | SOS1 (1.00) | SOS1 | |
| SCHEMBL23344987 | 0.90 | SOS1 (0.82) | SOS1 | |
| SCHEMBL29542579 | 0.90 | SOS1 (0.82) | SOS1 | |
| SCHEMBL23326352 | 0.90 | SOS1 (0.82) | SOS1 | |
| SCHEMBL23326351 | 0.90 | SOS1 (0.82) | SOS1 | |
| SCHEMBL23344938 | 0.88 | SOS1 (0.91) | SOS1 | |
| SCHEMBL23344992 | 0.88 | SOS1 (0.91) | SOS1 | |
| SCHEMBL23345154 | 0.86 | SOS1 (0.68) | SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4620531-A2 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-12258366-B2 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2025-03-25 | — | — | US | claimed |
| EP-4337678-A1 | USE OF SOS1 INHIBITORS WITH MTOR INHIBITORS TO TREAT CANCERS | Revolution Medicines, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | claimed |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | claimed |
| EP-4620531-A2 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250134891-A1 | USE OF SOS1 INHIBITORS WITH MTOR INHIBITORS TO TREAT CANCERS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-05-01 | — | — | US | disclosed |
| US-12258366-B2 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240277714-A1 | USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS | Revolution Medicines, Inc. | 2024-08-22 | — | — | US | disclosed |
| EP-4337678-A1 | USE OF SOS1 INHIBITORS WITH MTOR INHIBITORS TO TREAT CANCERS | Revolution Medicines, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-4319745-A1 | USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS | Revolution Medicines, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-11-16 | — | — | US | disclosed |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | Revolution Medicines, Inc. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168102-B1 | Bicyclic heteroaryl compounds and uses thereof | SOS1, SOST, SOS2 | SOS1 1/4885 |
| US-20230365605-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | SOS1 2/4885 |
| US-20240277714-A1 | USE OF SOS1 INHIBITORS WITH RAS INHIBITORS TO TREAT CANCERS | SOS1, HRAS, KRAS | SOS1 1/4885 |
| US-20210139517-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | SOS1 2/4885 |
| US-20250134891-A1 | USE OF SOS1 INHIBITORS WITH MTOR INHIBITORS TO TREAT CANCERS | SOS1, SOS2, MTOR | SOS1 1/4885 |
| US-12258366-B2 | Bicyclic heteroaryl compounds and uses thereof | SOST, SOS1, SOS2 | SOS1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.